Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

- Results suggest pirfenidone may provide meaningful clinical benefit in IPF patients -

- Results of new analyses of efficacy and safety reported -

- Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) -

SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) reported that results from the two Phase 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) were presented today in an oral late-breaker presentation at the International Conference of the American Thoracic Society (ATS) in San Diego. Dr. Paul Noble, co-chair of the CAPACITY program and Professor of Medicine and Chief of Pulmonary, Allergy and Critical Care Medicine at Duke University Medical Center presented details of data from CAPACITY that were previously announced by the company in a press release on February 3, 2009 as well as new information from the studies regarding the efficacy and safety of pirfenidone.

The primary endpoint of change in percent predicted Forced Vital Capacity (FVC) at Week 72 was met with statistical significance in CAPACITY 2 (p=0.001). The secondary endpoints of progression-free survival (PFS) and categorical change in FVC were also met with statistical significance. The primary endpoint was not met in CAPACITY 1 (p=0.501), but supportive evidence of a pirfenidone treatment effect was observed on a number of measures, including the primary endpoint. Pirfenidone was safe and generally well tolerated in both CAPACITY studies. InterMune is preparing a New Drug Application (NDA) expected to be submitted to the FDA in the summer of 2009, to be followed by a Marketing Authorization Application (MAA) submission to the EMEA around the end of 2009.

Dr. Noble commented on the results, "CAPACITY 2 demonstrated a statistic
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Cynosure, Inc. (Nasdaq: CYNO ... treatment systems for high-volume applications, today reported financial results ... 2014 financial results incorporate the acquisition of Palomar Medical ... Second-Quarter 2014 Financial Highlights ... , Non-GAAP net income of $7.1 million, or ...
(Date:7/29/2014)... 2014   What:   ... present data from a Phase I clinical trial of ... stop Parkinson,s disease progression. The Michael J. Fox Foundation ... will discuss the impact of the results for patients ... July 31, 2014         ...
(Date:7/29/2014)... , July 29, 2014  Drug development for ... rising incidence rates and the intense need for ... vaccine. Change is underway as the market moves ... highly effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
(Date:7/30/2014)... According to the Yeast Infection No More ... guide that will help candida sufferers get rid of their ... book uncovers to readers the truth about yeast infection and ... book, people will discover natural and safe remedies to relieve ... burning, and irritation of the vagina or vulva. , ...
(Date:7/30/2014)... 2014 The San Diego personal injury lawyers ... announcing that they are now offering free case reviews for ... asbestos exposure. , “Symptoms of asbestos exposure can take years ... 30 plus years ago may just now be suffering from ... Office of Melinda J. Helbock A.P.C. “We want people to ...
(Date:7/29/2014)... 30, 2014 VisitandCare.com today ... been added to the company’s exclusive network to help ... of joint efforts — as top fertility clinics in ... offer affordable, state-of-the-art, and successful IVF treatments. , The ... a comprehensive study by professionals at VisitandCare.com. The goal ...
(Date:7/29/2014)... Angeles, California (PRWEB) July 29, 2014 ... Education’ to senior communities with focus on Brain ... Aegis Living in Ventura. Brain Fitness Program Director ... lecture to Aegis Memory Care unit and the ... separate sessions. Aegis Life Enrichment Director Christy Rozsa ...
(Date:7/29/2014)... Hopkins researchers say they have discovered a chemical alteration ... that, if confirmed in larger studies, could give doctors ... risk of attempting suicide. , The discovery, described online ... that changes in a gene involved in the function ... significant role in turning what might otherwise be an ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3
... Bolling Air Force Base in Washington D.C., as well as a lecture ... ... Washington, D.C. (Vocus) July 2, 2008 -- The Drug Enforcement Administration ... Richard Nixon, who through an Executive Order established a single unified command ...
... QuadraBloc™, a new and improved version of AmWay's MagnaBloc. , ... ... a long-popular form of pain management, is now available in a ... ,"QuadraBloc has already been released in the United States, and will ...
... will be October 24-26, 2008 at the Catholic Institute in Toulouse, ... knowledge, ideas, applications and prospective issues in an interactive and collaborative ... http://www.ifats08.org for details. , ... Carmel, IN (PRWEB) ...
... using a combination of drugs targeting different parts of ... with severe lupus involving the kidneys, according to a ... Society of Nephrology (JASN). , "In our study, ... therapy for inducing complete remission of class V+IV lupus ...
... Clearance of Uniquely Integrated Meter/Pump System with ... and Compatible Software, WEST CHESTER, Pa., July ... its OneTouch(R) Ping(TM) Glucose Management System,by the U.S. ... the first,full-feature insulin pump that wirelessly communicates with ...
... of 300 human genomes in just over six months. The ... of genetic code that will be read by researchers worldwide, ... and disease. Scientists will be able to answer questions unthinkable ... be transformed. , The amount of data is remarkable: ...
Cached Medicine News:Health News:New MagnaBloc™ Product Available from Gradient Medical 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 3Health News:'Multi-target' immune therapy improves outcomes of severe lupus nephritis 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 3Health News:15 human genomes each week 2Health News:15 human genomes each week 3
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
... or antepartum GBS results can be available in ... revolutionary in vitro diagnostic test is the first ... in the clinical lab and near-patient by non-laboratory ... 24 hours a day, 365 days a year. ...
Medicine Products: